Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 10
Submit an article Journal homepage
304
Views
7
CrossRef citations to date
0
Altmetric
Original Articles: Research

The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia

Maria Giovanna ViliaDivision of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milano, Italy;
,
Eleonora FonteDivision of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milano, Italy;
,
Tania Veliz RodriguezDivision of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milano, Italy;
,
Marta TocchettiDivision of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milano, Italy;
,
Pamela RanghettiDivision of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milano, Italy;
,
Lydia ScarfòDivision of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milano, Italy; ;Vita-Salute San Raffaele University, Milano, Italy;
,
Nikos PapakonstantinouInstitute of Applied Biosciences, CERTH, Thessaloniki, Greece; ;Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
,
Stavroula NtoufaInstitute of Applied Biosciences, CERTH, Thessaloniki, Greece; ;Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
,
Kostas StamatopoulosInstitute of Applied Biosciences, CERTH, Thessaloniki, Greece; ;Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
,
Paolo GhiaDivision of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milano, Italy; ;Vita-Salute San Raffaele University, Milano, Italy;
&
Marta MuzioDivision of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milano, Italy; Correspondence[email protected]
 show all
Pages 2419-2425 | Received 01 Aug 2016, Accepted 04 Feb 2017, Published online: 28 Feb 2017

References

  • Sutton LA, Rosenquist R. The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia. Semin Cancer Biol. 2015;34:22–35.
  • Isaza-Correa JM, Liang Z, van den Berg A, et al. Toll-like receptors in the pathogenesis of human B cell malignancies. J Hematol Oncol. 2014;7:499–410.
  • Muzio M, Bertilaccio MTS, Simonetti G, et al. The role of toll-like receptors in chronic B-cell malignancies. Leuk Lymphoma. 2009;50:1573–1580.
  • Fonte E, Apollonio B, Scarfò L, et al. In vitro sensitivity of CLL cells to fludarabine may be modulated by the stimulation of Toll-like receptors. Clin Cancer Res. 2013;19:367–379.
  • Frenquelli M, Muzio M, Scielzo C, et al. MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. Blood. 2010;115:3949–3959.
  • Ntoufa S, Vardi A, Papakonstantinou N, et al. Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors. Mol Med. 2012;18:1281–1291.
  • Muzio M, Scielzo C, Bertilaccio MTS, et al. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br J Haematol. 2009;144:507–516.
  • Riva F, Bonavita E, Barbati E, et al. TIR8/SIGIRR is an interleukin-1 receptor/toll like receptor family member with regulatory functions in inflammation and immunity. Front Immun. 2012;3:322.
  • Xiao H, Gulen MF, Qin J, et al. The toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. Immunity. 2007;26:461–475.
  • Garlanda C, Riva F, Veliz T, et al. Increased susceptibility to colitis-associated cancer of mice lacking TIR8, an inhibitory member of the interleukin-1 receptor family. Cancer Res. 2007;67:6017–6021.
  • Bertilaccio MTS, Simonetti G, Dagklis A, et al. Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models. Blood. 2011;118:660–669.
  • Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–5456.
  • Apollonio B, Bertilaccio MTS, Restuccia U, et al. From a 2DE-gel spot to protein function: lesson learned from HS1 in chronic lymphocytic leukemia. J Vis Exp. 2014;e51942–e51942.
  • Arvaniti E, Ntoufa S, Papakonstantinou N, et al. Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients. Haematologica. 2011;96:1644–1652.
  • Kadota C, Ishihara S, Aziz MM, et al. Down-regulation of single immunoglobulin interleukin-1R-related molecule (SIGIRR)/TIR8 expression in intestinal epithelial cells during inflammation. Clin Exp Immunol. 2010;162:348–361.
  • Stacchini A, Aragno M, Vallario A, et al. MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res. 1999;23:127–136.
  • Gutierrez A, Tschumper RC, Wu X, et al. LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. Blood. 2010;116:2975–2983.
  • Zhu YY, Su Y, Li ZG, et al. The largely normal response to Toll-like receptor 7 and 9 stimulation and the enhanced expression of SIGIRR by B cells in systemic lupus erythematosus. PLoS One. 2012;7:e44131.
  • Fonte E, Agathangelidis A, Reverberi D, et al. Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation. Haematologica. 2015;100:1460–1468.
  • Kanduri M, Cahill N, Göransson H, et al. Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood. 2010;115:296–305.
  • Malik A, Shoukier M, Garcia-Manero G, et al. Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study. Clin Lymph Myeloma Leuk. 2013;13:292–295.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.